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Abstract Type 2 diabetes (T2D) and prediabetes have a
major global impact through high disease prevalence,
significant downstream pathophysiologic effects, and enor-
mous financial liabilities. To mitigate this disease burden,
interventions of proven effectiveness must be used. Evidence
shows that nutrition therapy improves glycemic control and
reduces the risks of diabetes and its complications. According-
ly, diabetes-specific nutrition therapy should be incorporated
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Evidence-based recommendations for healthy lifestyles
that include healthy eating can be found in clinical
practice guidelines (CPGs) from professional medical
organizations. To enable broad implementation of
these guidelines, recommendations must be recon-
structed to account for cultural differences in lifestyle,
food availability, and genetic factors. To begin, pub-
lished CPGs and relevant medical literature were
reviewed and evidence ratings applied according to
established protocols for guidelines. From this infor-
mation, an algorithm for the nutritional management
of people with T2D and prediabetes was created. Sub-
sequently, algorithm nodes were populated with trans-
cultural attributes to guide decisions. The resultant trans-
cultural diabetes-specific nutrition algorithm (tDNA)
was simplified and optimized for global implementation
and validation according to current standards for CPG
development and cultural adaptation. Thus, the tDNA is
a tool to facilitate the delivery of nutrition therapy to
patients with T2D and prediabetes in a variety of cul-
tures and geographic locations. It is anticipated that this
novel approach can reduce the burden of diabetes, improve
quality of life, and save lives. The specific Southeast Asian
and Asian Indian tDNAversions can be found in companion
articles in this issue of Current Diabetes Reports.
Keywords Diabetes.Diet.Glycemiccontrol.Nutrition.
Transcultural.Prediabetes
Introduction
Type 2 diabetes (T2D) and prediabetes impose a huge
burden of illness on developed and developing nations
through high disease prevalence (6.6% overall, >10% in
many countries), direct and indirect multisystem pathophys-
iologic effects, and financial liabilities (US$376 billion an-
nually worldwide) [1]. This enormous disease burden can be
reduced by deliberate application of interventions with prov-
en effectiveness [2–14]. Ideally, diagnostic and therapeutic
interventions should be accessible, facile, affordable, cost-
effective, and culturally sensitive [1]. To improve efficiency,
they can be combined in coordinated disease management
programs. Lifestyle management, including physical activi-
ty and diabetes-specific nutrition therapy, is an essential and
necessary component of any comprehensive care plan for
diabetes [15￿￿, 16, 17]. Care plan implementation is facili-
tated by clinical practice guidelines (CPGs) intended to
inform clinical decisions, standardize and optimize patient
care, improve outcomes, and control costs [18, 19]. Recom-
mendations within CPGs should be evidence-based, precise,
clear, relevant, authoritative, and compatible with existing
norms [20, 21￿￿]. The purpose of this report is to de-
scribe pertinent background material and the development
process of a transcultural diabetes-specific nutrition algo-
rithm (tDNA) that can facilitate portability of evidence-
based recommendations to better enable their implemen-
tation and validation across a broad geographic and cul-
tural spectrum.
Benefits and Problems Associated with CPGs
Although CPGs may have distinct flaws or problems
intrinsic to their development, interpretation, and im-
plementation, they are useful tools to aid clinical deci-
sion making and improve patient care [21￿￿, 22–26].
Benefits are derived from the characteristics and attrib-
utes of the CPGs. For example, authoritative guidelines
are developed by expert panels from specialized areas
of medicine and reflect group consensus on specific
aspects of patient care. These CPGs are evidence-
based, transparently incorporating relevant research
findings, and contain recommendations with the great-
est potential for superior clinical outcomes. Depending
on the methodology used, CPGs may consider subjec-
tive factors such as risk-benefit perceptions and cost-
effectiveness. They may also engage such principles as
middle-range question-oriented literature searching, patient-
oriented evidence, cascades of recommendations for a partic-
ular clinical question based on variations in clinical set-
tings, multiple levels of review, and diligent screening
of writers and reviewers with respect to credentialing
and conflicts of interest [21￿￿]. Through these exacting meth-
odologies and resultant credible content, CPGs empower
practitioners, patients, and the larger universe of other health
care stakeholders to make better decisions regarding the ap-
plicability of care.
CPGs also have limitations [1, 19, 27]. Even if their
recommendations are appropriate, their implementation
and performance can be impeded by untimeliness, complex-
ity, and/or incompatibility with other recommendations.
Their adoption and adherence may be further hindered by
idiosyncratic physician and patient attitudes as well as the
unique characteristics of a practice setting [28]. Guidelines
may not accommodate disruptions in the continuity of care
that arise among health care providers, facilities, and time
frames [29]. Moreover, selected recommendations may re-
flect only a professional perspective, which may discount
patient predilections or values and compromise clinical ad-
herence and outcomes [19, 28]. Finally, CPGs may not be
able to be generalized for all patients or populations. Patient
age, gender, and genomics, as well as culture, customs, and
environment, must be factored into any decision to apply a
particular recommendationto a particular patient in a particular
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divergent clinical settings. In light of the globalization and
impact ofthe diabetes epidemic, this significant problem must
be resolved.
Addressing the Portability Problem
Whenever possible, either de novo or the most recent up-to-
date CPGs on a particular topic should be used as a resource
for specific patient management issues [30]. For ease of
implementation, the CPGs should be straightforward and
readily understood [20]. Derivative products (i.e., decision
trees, flow charts, or algorithms) can be used to reduce the
complexity of comprehensive CPGs, aid comprehension,
and facilitate successful implementation and validation
[31–33]. Such tools not only improve the standardization
of care, but also help to coordinate the activities of all
members of a treatment team for patients with diabetes. A
diabetes flow sheet was shown to increase CPG adherence
in a recent outcomes study based on medical audits [34].
Transcultural Factors
To address the problem of generalizability and the effect of
cultural differences among patients on a global scale, CPG
development must begin with a robust decision-tree tem-
plate amenable to strategic modification that does not sacri-
fice performance. Thus, the tDNA template was designed
for the optimization of nutritional care for patients with T2D
and prediabetes on a global scale (Fig. 1, Tables 1, 2, 3, 4, 5,
6 and 7)[ 15￿￿, 35–40, 41￿￿, 42]. This instrument extends
evidence-based nutritional recommendations from the
American Association of Clinical Endocrinologists (AACE)
[15￿￿, 43] and the American Diabetes Association (ADA)
[41￿￿] and provides nodes that can be populated with infor-
mation based on geographic and ethnocultural factors for
individualization and implementation at regional and local
levels worldwide. The tDNA is intended to 1) increase
awareness of the benefits of nutritional interventions for
patients with T2D and prediabetes; 2) encourage healthy
dietary patterns that accommodate regional differences in
genetic factors, lifestyles, foods, and cultures; 3) enhance
the implementation of existing CPGs for T2D and predia-
betes management; and 4) simplify nutritional therapy for
ease of application and portability.
Methodology to Develop the tDNA
The methods and procedures used to develop the tDNA
are widely recognized as state-of-the-art within medical
organizations and were rigorously applied throughout
this endeavor. The task force chair initiated the project
via live meetings and telephone or digital communications.
Internationally respected health care experts in diabetes and
nutrition from Brazil, Canada, China, Mexico, The Nether-
lands, Panama, Spain, Taiwan, and the United States were
identified through literature searches and peer recommenda-
tions. Each expert was contacted, briefed on the project, and
questioned about his or her current activities and interest in
participating in the program. Based on responses, invitations
were extended until a complement of specialists, sufficient for
advisory activities, accepted the request to be included in the
task force.
Members of the task force provided data, culturally mean-
ingful information, and expert opinion to guide algorithm de-
velopment. During a meeting in New York City on November
12 to 13, 2010, members discussed clinical evidence and
the influence of various diabetes risk factors and comor-
bidities (cardiovascular events, obesity, hypertension,
and dyslipidemia) in the construction of the tDNA tem-
plate. Task force members also deliberated over the
relative merits of specific metrics (body weight, waist-
to-hip ratio [WHR], fasting blood glucose, and glycosylated
hemoglobin [HbA1c]) and nutritional therapies (foods, diets,
and calorie supplementation and replacement with prepared
diabetes-specific formulas) that would be cited in the tem-
plate. Diabetes-specific formulas (glycemia-targeted special-
ized nutrition formulas) may be used for calorie replacement
or supplementation as part of medical nutrition therapy
(MNT). Transcultural factors influencing dietary practices,
food choices, and diabetes health care interventions were also
considered. For example, energy-dense fast foods are ubiqui-
tous but may take different forms throughout the world. Like-
wise, healthy foods take different forms based on geography
and seasonality. Table 8 lists common international foods and
their glycemic indices [44]. Such information becomes essen-
tial at the local level to make nutritional therapy meaningful.
The evidence supporting task force recommendations
was rated and assigned a numerical descriptor according to
levels of scientific substantiation provided by the 2010
AACE protocol for the development of CPGs (Table 9)
[21￿￿]. The cumulative information was then codified using
an alphabetic descriptor (grade A, B, C, D), reflecting the
respective strength of the recommendation [21￿￿]. The data
and information used to construct the algorithm, as well as
the included recommendations, closely reflect similar infor-
mation and grading found in the diabetes nutrition sections
of the AACE [15￿￿, 43] and ADA [41￿￿] CPGs.
Following the initial task force meeting, a subcommittee
reviewedameetingtranscripttoadoptpointsofagreementand
resolve points of disagreement to achieve consensus on all
major topics of discussion. Subsequently, all task force mem-
bers received abstract summaries of the proceedings for their
182 Curr Diab Rep (2012) 12:180–194review and subsequent modification or approval. Consensus
recommendations were discussed at a second task force meet-
ingheldonJune17to18,2011inNewYorkCity.Atthattime,
recommendations were critiqued, refined, and prepared for
transcultural adaptation by an expanded task force team that
included additional experts from Canada, India, and Spain.
Fig. 1 Transcultural medical nutrition algorithm for prediabetes and
type 2 diabetes. AACE—American Association of Clinical Endocri-
nologists; ADA—American Diabetes Association; BMI—body mass
index; DASH—Dietary Approaches to Stop Hypertension; FPG—
fasting plasma glucose; HbA1c—glycosylated hemoglobin A1c; IFG
—impaired fasting glucose; IGT—impaired glucose tolerance; MNT—
medical nutrition therapy; OGTT—oral glucose tolerance test; PG—
plasma glucose; WC—waist circumference; WHR—waist-to-hip ratio
Curr Diab Rep (2012) 12:180–194 183Transculturalization Standards
The transculturalization of CPGs addresses problems
that arise when recommendations are considered for
implementation in an environment beyond that of the
sponsoring individuals or organization [45]. In regard to
nutrition therapy, transcultural factors relate to genetic
differences within a given population, food preferences,
religious practices,socioeconomic status, and others. Attrib-
utes of the transculturalization process should include
evidence-based methodology, scientific rigor, transparen-
cy, relevance, and authority commensurate with the
original CPGs [30, 46–50]. To obtain the cooperation
and acceptance of key regional stakeholders in the
implementation of the CPGs, their participation in the
transculturalization process is essential. Likewise, a
mechanism to have regional experts train local stake-
holders and then continue the iterative process is vital,
along with a validation and evaluation process to fur-
ther modify the CPGs, if needed [50, 51]. To accom-
modate patient opinion and choice, subjective patient
preferences for health care interventions that are locally
available should be considered [52–54], as well as
cascades of alternative strategies for a specific action
[55, 56] and patient aids to inform their decisions [53].
Table 1 Classification of body composition by BMI, WC, and disease
risk for Caucasians
BMI,
kg/m
2
Obesity
class
Disease risk
WC:
M≤40 in
WC:
M>40 in
F≤35 in F>35 in
Underweight <18.5
Normal 18.5–24.9
Overweight 25.0–29.9 Increased High
Obese 30.0–34.9 I High Very high
35.0–39.9 II Very high Very high
Extremely
obese
≥40 III Extremely
high
Extremely
high
BMI body mass index; F female; M male; WC waist circumference
(Adapted from: Bantle JP, Wylie-Rosett J, Albright AL, et al. Nutrition
recommendations and interventions for diabetes: a position statement
of the American Diabetes Association. Diabetes Care. 2008;31 Suppl
1:S61–78) [41￿￿]
Table 2 Classification of body composition by BMI, WC, and disease
risk for Southeast Asians and Asian Americans
BMI,
kg/m
2
Obesity class Disease risk
WC:
M≤90 cm
WC:
M>90 cm
F≤80 cm F>80 cm
Underweight <18.5
Normal 18.5–22.9 Average Average
Overweight 23–24.9 I Increased High
Obese 25.0–29.9 II High Very high
Very high Very high
Extremely obese ≥30 III Severe Severe
BMI body mass index; F female; M male; WC waist circumference
(Adapted from: Wildman RP, Gu D, Reynolds K, et al. Appropriate
body mass index and waist circumference cutoffs for categorization of
overweight and central adiposity among Chinese adults. Am J Clin
Nutr. 2004;80:1129–36) [36]
(Adapted from: Appropriate body-mass index for Asian populations
and its implications for policy and intervention strategies. WHO Expert
Consultation. Lancet. 2004;363:157–63) [37]
Table 3 Physical activity guidelines for the management of diabetes
Intensity
level
Physical activity
Low Patients should be encouraged to achieve an active
lifestyle and to avoid sedentary living, because physical
activity and exercise provide many health benefits and
facilitate glycemic control. Participation in any physical
activity provides some health benefits
For substantial benefits:
≥150 min/week of moderate-intensity activity, or
≥75 min/week of vigorous-intensity aerobic activity, or
some combination of equivalent moderate/vigorous
activity
Medium Aerobic activity should be performed in episodes of
≥10 min and preferably spread throughout the week
For additional, more extensive benefits:
≥300 min/week of moderate-intensity activity, or
≥150 min/week of vigorous-intensity aerobic activity, or
some combination of equivalent moderate/vigorous
activity
additional health benefits are gained beyond this amount
High Moderate- or high-intensity resistance exercise training
for all major muscle groups, as a separate modality from
aerobic exercise, has been shown to increase muscle
mass and strength, alter body composition, and improve
glycemic control; therefore, it should be combined with
aerobic activity in each individual ≥2 days per week
Exercise should be undertaken only after cardiac clearance has been
obtained
(Adapted from: US Department of Health and Human Services. 2008
Physical activity guidelines for Americans. 2008. http://www.health.
gov/paguidelines/guidelines/summary.aspx. Accessed June 22, 2011)
[35]
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On July 8, 2011, clinical experts from the Philippines, Hong
Kong, Indonesia, Malaysia, Taiwan, Singapore, and Thai-
land met in Taipei, Taiwan to learn about the tDNA and
begin the process of adapting the algorithm to their territo-
ries. This transcultural group was composed of endocrinol-
ogists, dietitians, and primary care practitioners who
represented the health care specialties serving the patient
populations that were targeted for the adaptive process.
During the meeting, participants received information on
diabetes and lifestyle modification, nutrition therapy and
related clinical outcomes, and tDNA program goals and
objectives. A point-by-point review of the algorithm was
undertaken to explore pathways, content, and supportive
evidence and to elicit information for the cultural adaptation
of the algorithm and related recommendations for Southeast
Asian patients. Subcommittee meetings were subsequently
held in Taiwan (July 18, 2011) and India (September 23,
2011)toexplicitlypopulatethe nodes ofthe algorithm and the
cells of the calorie supplement/replacement matrix (Table 5)
with specific transcultural information and recommendations
fortheirrespectiveregions.Companionarticlesinthisissueof
Current Diabetes Reports describe the adaptive process and
related output [57, 58].
Results
An amalgam of the deliberations and conclusions of the
expanded international task force is presented here,
displaying the consensus composite template of the
tDNA, which is being used in the transculturalization
process. Adaptations will be considered in ongoing re-
gional meetings until provincial versions of the algorithm
are available for local implementation and validation through-
out the world.
Table 4 AACE/ADA nutritional guidelines for the management of
diabetes
Hypocaloric (weight loss) diet: 250–1000 kcal/d deficit
Target: decrease weight by 5% to 10% for overweight/obese, 15% for
class 3 obesity
Target: decrease BMI by 2 to 3 units
Carbohydrates (preferably low-glycemic index): 45% to 65% daily
energy intake and not less than 130 g/d in patients on low calorie diet
Protein: 15% to 20% daily energy intake
Dietary fat: <30% daily energy intake
Saturated fat: <7% daily energy intake
Cholesterol: <200 mg/d
Fiber: 25–50 g/d
Trans fats: minimize or eliminate
AACE American Association of Clinical Endocrinologists; ADA Amer-
ican Diabetes Association; BMI body mass index
(Adapted from: National Guideline Clearinghouse. Guideline synthe-
sis: Nutritional management of diabetes mellitus. 2009. http://www.
guideline.gov.syntheses/synthesis.aspx?id+16430. Accessed June 22,
2011.) [40]
Table 5 Diabetes-specific (glycemia targeted specialized) nutrition
formulas for the management of prediabetes and diabetes
Overweight/
obese
Use 2 to 3 diabetes-specific nutrition formulas
a as part
of a reduced calorie meal plan, as a calorie replace-
ment for meal, partial meal, or snack (grade C;
LOE 3)
Calorie goals:
<250 lb01200 to 1500 calories
>250 lb01500 to 1800 calories
Calories from diabetes-specific nutrition formulas
Calories from other healthy dietary source
Normal
weight
Uncontrolled
diabetes
1 to 2 diabetes-specific nutrition formu-
las per day to be incorporated into a
meal plan, as a calorie replacement for
meal, partial meal, or snack (grade D;
LOE 4)
HbA1c>7%
Controlled
diabetes
Use of diabetes-specific nutrition formu-
las should be based on clinical judg-
ment and individual assessment
b
(grade D; LOE 4)
HbA1c≤7%
Underweight Use diabetes-specific nutrition supplements
c 1t o3
units/d per clinical judgment based on desired rate
of weight gain and clinical tolerance (grade D;
LOE 4)
LOE 1: data defined as conclusive results from prospective, random-
ized controlled trials that have large subject populations representative
of the target population and results that are easily generalized to the
target population. Data also include results from meta-analyses of
randomized controlled trials, results from multicenter trials, and “all
or none” evidence; LOE 2: data include conclusive results from indi-
vidual randomized controlled trials that have limited subject numbers
or target population representation; LOE 3: data include all other
conclusive clinical findings from nonrandomized studies, studies with-
out controls, and nonexperimental or observational studies. These data
may require interpretation and, by themselves, are not compelling;
LOE 4: data are defined as information based solely on experience or
expert opinion and are not necessarily substantiated by any conclusive
scientific data. Frequently, only LOE 4 data are available
aDiabetes-specific nutrition formulas are nutritional products used as
replacement for meals, partial meals, or snacks to replace calories in
the diet
bIndividuals who may have muscle mass and/or function loss and/or
micronutrient deficiency may benefit from diabetes-specific nutrition
supplements. Individuals who need support with weight maintenance
and/or a healthy meal plan could benefit from diabetes-specific
nutrition
cDiabetes-specific nutrition supplements are complete and balanced
nutritional products used in addition to a typical meal plan, to help
promote increased nutritional intake
HbA1c glycosylated hemoglobin A1c; LOE level of evidence
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Diets, meals, and foods influence glycemic status and the
risk of diabetic complications (grade A) [16, 59–61].
R2
MNT is important and should be implemented as an essen-
tial component of comprehensive management programs for
all patients with T2D and prediabetes (grade A) [41￿￿, 43,
62–67].
R3
Diets should be based on individual risk factors for impaired
glucose tolerance, obesity, hypertension, and dyslipidemia
(grade A) [64, 65, 67, 68].
R4
Cultural factors should guide the selection of local
foods and meals to adhere with general nutrition recom-
mendations from the AACE and ADA (grade D) [1,
41￿￿, 43].
R5
Diabetes-specific formulas may be used for calorie re-
placement or supplementation as part of MNT (grade A)
[41￿￿, 43, 69￿, 70, 71]. Prepared and packaged diabetes-
specific formulas contain nutrients that are designed to
facilitate glycemic control [69￿]. Such nutrients include
modified maltodextrin, fructose, fiber, soy protein,
monounsaturated fatty acids, and antioxidants. Clinical
studies have demonstrated improvements in glycemic
profiles and reductions in disease complications among
patients who consume prepared formula products as part
of MNT. For patients with low body mass index (BMI)
and/or insufficiency states, such as the elderly, caloric
supplementation is helpful for weight gain, amelioration
of nutritional deficiencies, and prevention of diabetic
complications [69￿, 72–75]. For patients with normal
or elevated BMI, caloric replacement is helpful to
achieve weight loss, greater metabolic control, and avoid-
ance of subtle deficits of vitamins or other nutrients that can
accompany simple calorie restriction [69￿]. Intensifica-
tion or reduction in the number of replacements and
supplements is a stepped process based on clinical appraisals
and modification of regimens to meet individual patient goals
[73].
Table 6 Criteria for bariatric surgery for the management of diabetes
BMI≥40 kg/m
2 (about 100 lb overweight for men and 80 lb for
women) or
BMI 35–39.9 kg/m
2 and an obesity-related comorbidity, such as T2D,
coronary heart disease, or severe sleep apnea
BMI 30–34.9 kg/m
2 under special circumstances
According to the International Diabetes Federation, bariatric surgery
should be considered an alternative treatment option in patients with
a BMI of 30–35 kg/m
2 when diabetes is not adequately controlled by
a medical regimen and especially when there are cardiovascular
disease risk factors
Consideration may be given to laparoscopic-assisted gastric banding in
patients with T2D who have a BMI>30 kg/m
2 or Roux-en-Y gastric
bypass for patients with a BMI>35 kg/m
2 to achieve at least short-
term weight reduction
And for each of the above:
Failure to achieve and sustain weight loss after attempts at lifestyle
modification
Tolerable operative risks
Understanding of operation
Commitment to treatment and long-term follow-up
Acceptance of required lifestyle changes
BMI body mass index; T2D type 2 diabetes
(Adapted from: Weight-control Information Network—an information
service of the National Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK). Bariatric surgery for severe obesity. 2009. http://
win.niddk.nih.gov/publications/gastric.htm. Accessed November 14,
2011) [38]
(Adapted from: International Diabetes Federation. Bariatric surgical
procedures and interventions in the treatment of obese patients with
type 2 diabetes: a position statement from the International Diabetes
Federation Taskforce on Epidemiology and Prevention. http://www.idf.
org/webdata/docs/IDF-Position-Statement-Bariatric-Surgery.pdf.
Accessed June 27, 2011) [39]
(Adapted from: Handelsman Y, Mechanick JI, Blonde L, et al. Amer-
ican Association of Clinical Endocrinologists Medical Guidelines for
Clinical Practice for developing a diabetes mellitus comprehensive care
plan. Endocr Pract. 2011;17 Suppl 2:1–53) [15￿￿]
Table 7 Antihypertensive diet: daily nutrient goals used in the DASH
studies
Carbohydrate 55% of calories
Total fat 27% of calories
Protein 18% of calories
Saturated fat 6% of calories
Cholesterol 150 mg
Fiber 30 g
Sodium 1500 mg
Potassium 4700 mg
Calcium 1250 mg
Magnesium 500 mg
DASH Dietary Approaches to Stop Hypertension
Based on a 2100-calorie eating plan
(Adapted from: US Department of Health and Human Services. Your
guide to lowering your blood pressure with DASH. NIH publication
no. 06-408. 2006. http://www.nhlbi.nih.gov/health/public/heart/hbp/
dash/new_dash.pdf. Accessed June 22, 2011) [42]
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Geographic location and ethnocultural classifications should
be used to tailor the algorithm for specific patient popula-
tions. Risk factors are the leading determinants of patient
pathways and related recommendations; one or more risk
factors identify patients who are more likely to experience
disease progression and/or complications (grade A) [75–77].
Dietary modification can mitigate the following risk factors:
T2D or prediabetes, excessive weight or obesity, hyperten-
sion, and dyslipidemia (grade A) [64, 65, 67].
R7
Anthropometric measures—BMI, waist circumference
(WC), or WHR—should be used to assess body composi-
tion and risk of progression [41￿￿]. Although each of these
measures has merit in clinical practice, differences in values
and interpretations arising from phenotypic and cultural dif-
ferences among populations have confounded global stan-
dardization. Likewise, difficulty using some methods (eg,
WHR) has created regional preferences in medical practice
and influenced general recommendations. Consequently,
BMI and WC were chosen as the preferred prioritized meas-
ures of body composition in the algorithm. Values for nor-
mal and abnormal composition can be adjusted via
ethnocultural inputs for local applicability (grade B) [78, 79].
R8
Irrespective of patient risk factors, lifestyle intervention
mandates professional counseling, physical activity, and
healthy eating patterns consistent with current CPGs or
evidence (grade A) [41￿￿, 43]. Professional counseling
may be impeded by local attitudes and costs as well as the
lack of perceived value by patients who may be
Table 8 Common international foods and glycemic indices
Carbohydrate
foods
Glycemic
index
Glycemic
index
Common foods Fruits
White wheat
bread
75 Apple 36
Whole wheat
bread
74 Banana 51
Multigrain bread 53 Dates 42
Wheat roti 62 Mango 51
Chapati 52 Orange 43
Corn tortilla 46 Peaches 43
White rice 73 Pineapple 59
Brown rice 68 Watermelon 76
Barley 28 Vegetables
Corn 52 Potato, boiled 78
Spaghetti 49 Potato, instant
mash
87
Rice noodles 53 Potato, fried 63
Udon noodles 55 Sweet potato 63
Couscous 65 Carrots, boiled 39
Dairy products Pumpkin, boiled 64
Whole milk 39 Plantain 55
Skim milk 37 Taro, boiled 53
Soy milk 37 Vegetable soup 48
Rice milk 86 Legumes
Ice cream 51 Chickpeas 28
Yogurt 41 Kidney beans 24
Cereals Lentils 32
Cornflakes 81 Soy beans 16
Rolled oat meal 55 Snacks
Instant oat meal 79 Chocolate 40
Rice congee 78 Popcorn 65
Muesli 57 Potato chips 56
Millet porridge 67 Soda 59
Biscuits 69 Rice crackers 87
Glycemic index (GI) ranks carbohydrates according to their effect on
blood glucose levels. High GI0≥70; medium GI056–69; low GI0≤55
(Adapted from: Atkinson FS, Foster-Powell K, Brand-Miller JC. In-
ternational tables of glycemic index and glycemic load values: 2008.
Diabetes Care. 2008;31:2281–3. 45. Baker R, Feder G. Clinical guide-
lines: where next? Int J Qual Health Care. 1997;9:399–404) [44]
Table 9 Levels of sub-
stantiation and their re-
spective numerical and
semantic descriptors
RCT randomized con-
trolled trial
(Adapted from: Mechanick
JI,Camacho PM, Cobin
RH, et al. American
Association of Clinical
Endocrinologists Pro-
tocol for Standardized
Production of Clinical
Practice Guidelines—
2010 update. Endocr
Pract. 2010;16:270–83)
[21￿￿]
Level of
evidence
Study design or
information type
1 RCTs
1 Meta-analyses of RCTs
2 Nonrandomized RCTs
2 Meta-analyses of
nonrandomized RCTs
2 Prospective cohort
studies
2 Retrospective case–
control studies
3 Cross-sectional study
3 Surveillance study
3 Consecutive case series
3 Single case report
4 Expert consensus
4 Expert opinion based on
experience
4 Theory-driven
conclusions
4 Experience-based
information
4 Review
Curr Diab Rep (2012) 12:180–194 187economically disadvantaged. Although both low-risk and
high-risk patients should comply with these basic recom-
mendations, high-risk patients should intensify their efforts
according to their specific needs and conditions.
R9
A registered dietitian (RD) who is familiar with the compo-
nents of MNT should be involved in patient management
(grade B) [41￿￿]. Long-term changes in behavior are diffi-
cult to achieve for many patients. To assist implementation,
physicians should encourage and support patients through
the behavior modification process. However, physicians are
limited by time and experience in behavior modification
techniques. Therefore, the use of other health care profes-
sionals with expertise in patient self-management may be
necessary. Research has shown that lifestyle case manage-
ment by RDs can improve health outcomes among patients
with T2D [80, 81￿, 82]. In cultures and regions (e.g., Hong
Kong) where patients may oppose or decline nutrition con-
sultation by health care providers who are not physicians, we
encourage physicians to develop skills in nutrition medicine
by participating in appropriate continuing medical education.
R10
Patients should be encouraged to lead an active lifestyle and
avoid sedentary living, as physical activity and exercise in-
dependently confer health benefits and facilitate glycemic
control (grade A) [35, 83–85]. Substantial benefit is achieved
with ≥150 min per week of moderate activity or ≥75 min per
week of vigorous aerobic activity [83–86]. Resistance exer-
cise training, as a separate modality from aerobic exercise,
can increase muscle mass and improve glycemic control and
should be combined with aerobic activity (grade D) [87].
Additional time spent on any physical activity can augment
benefit and represents an intensification strategy for patients
with higher risk stratification or those who do not achieve
their goals with less intense activity.
R11
MNT was introduced in 1994 by the American Dietetic
Association to better express the concept of therapeutic
nutrition [65, 88]. It consists of specific nutritional inter-
ventions that include assessment, counseling, and dietary
modification, with and without specialized nutritional for-
mulas for calorie supplementation or replacement [65].
Diabetes-specific MNT has been considered a cornerstone
of diabetes treatment because it can improve glycemic pro-
files and reduce the risk of disease complications [65, 67,
89]. Formalized recommendations for T2D in the medical
literature include the following: carbohydrates, preferentially
from low-glycemic index foods, for 45% to 65% of
daily energy intake and not less than 130 g/day in
patients on low-calorie diets (grade D) [41￿￿, 43, 90,
91]; fats for less than 30% of daily energy intake (grade
D) [41￿￿, 43, 90]; saturated fat for less than 7% of daily
energy intake (grade A) [41￿￿, 43, 90, 92]; protein for
15% to 20% of energy intake and not less than 1 g/kg
in patients with normal kidney function (grade D) [41￿￿,
43]; cholesterol restricted to less than 200 mg daily (grade
A) [41, 43, 90, 92]; trans fats eliminated or reduced to min-
imal intake (grade D) [41￿￿, 43, 90, 92]; and fiber for 25 to
50 g daily (grade A) [41￿￿, 43, 90].
R12
Overweight or obese patients should adhere to these guide-
lines and try to achieve a gradual weight loss of 5% to 10%
by reducing caloric intake, for a total daily deficit of 250 to
1000 kcal (grade A) [15￿￿, 16, 17, 41￿￿, 43, 70, 93, 94].
Patients with class 3 obesity should shed 15% of body
weight (grade D) [15￿￿, 16, 17, 41￿￿, 43, 70, 93, 94]. BMI
should be decreased by 2 to 3 units (grade D) [41￿￿, 43, 70,
93, 94]. Any amount of weight loss is associated with
metabolic benefits, even if clinical targets are not met.
R13
Bariatric surgery may be considered for patients with T2D
and obesity who 1) fail to respond to lifestyle and pharma-
cologic interventions; 2) meet established criteria related to
body composition, comorbidities, and surgical risk; and 3)
commit to durable lifestyle changes and follow-up evalua-
tions [95–98]. The recent statement by the International
Diabetes Federation on criteria for bariatric surgery should
be considered when making treatment decisions [39].
R14
Patients with T2D or prediabetes complicated by hyperten-
sion require further nutritional management. Sodium intake
should already be limited to 1,500 mg/day per recent rec-
ommendations provided by the Dietary Guidelines for
Americans, 2010 (grade A) [99–102, 103￿, 104]. The prin-
ciples of the Dietary Approaches to Stop Hypertension
(DASH) diet, particularly increasing the consumption of
fresh fruits and vegetables, should also be incorporated into
the patient’s diet.
R15
Patients with lipid abnormalities must pay closer attention to
fat intake based on their dyslipidemic profiles and may
benefit from viscous fibers and plant sterols (grade A) [91,
188 Curr Diab Rep (2012) 12:180–19492, 105–111]. The reduction of simple sugars and alcohol is
important for patients with hypertriglyceridemia.
R16
When multiple comorbidities exist in a patient with T2D or
prediabetes, recommended interventions are applied simul-
taneously and at a higher level of intensity, but individual
patient factors, such as potential for adherence, adverse
effects, and dietary customs and practices, are also taken
into account (grade D).
R17
Follow-up evaluations for all patients should occur at appro-
priate intervals depending on need (grade D). Assessments
should include a history and physical examination (anthropo-
metrics, blood pressure); blood chemistries (glucose, HbA1c,
lipids, renal function, and liver enzymes depending onclinical
status); and urinary microalbumin determination. Improve-
ments in disease states based on follow-up assessments create
anopportunitytodiminishtheintensityofinterventionsandto
spare resources. Although deterioration of clinical status cre-
ates a need to increase the intensity of interventions, it also
creates an opportunity to search for ways to improve care and
possibly adherence.
Discussion
WithinNorthAmerica,thenationalprevalenceofdiabetesand
prediabetes rangesfrom10.1% inMexicoto11.6%inCanada
and 12.3% in the United States [1]. The global prevalence is
significantly lower, at6.6%,butratesinthe Arabcountries are
much higher at 13.4% (Oman) to 18.7% (United Arab Emi-
rates)[1].Thesefiguresreflectaccurateestimatesofthesizeof
affected populations, but do not convey the complexities that
underliethe epidemiologyofthe disease.Hiddenbehindthese
numbers are the details that illuminate the nature of the prob-
lem. Today, societies are heterogeneous not only in North
America, but in many other places around the world. Con-
tinents, countries, states, municipalities, and even neighbor-
hoods can be characterized by ethnicity, customs, mores,
habits, and beliefs. All of these demographics influence per-
sonal choices that contribute to health or illness and the
prevention or development and perpetuation of diabetes.
Health care providers must understand the culture of
diabetes to effectively manage their patients with diabetes.
Although general cultural sensitivity training is offered in
medical school and through postgraduate activities, most
practitioners are woefully deficient in the knowledge and
skill to maneuver medically through the intricacies of a
diverse patient population [112–115]. Clinical guidance
rarely cites the cultural differences that truly matter in the
delivery of health care. This may be especially true—and
particularly important—with respect to diabetes, a disease
that is intimately associated with lifestyles and foods. For
these reasons, the international task force sought to identify
and incorporate regional differences in genetic factors, diet,
exercise, and culture into CPGs for nutrition therapy in T2D
and prediabetes.
For example, based on clinical evidence, it was abundantly
clear to the task force members that a principal cause of
obesity and diabetes was the consumption of energy-rich or
fast foods. Such foods are characterized by high concentra-
tions of fats and refined carbohydrates with high glycemic
indices. Describing foods in terms of composition, however,
maylimitcomprehensionandcorrectiveaction.Instead,citing
examples that are culturally meaningful (e.g., fried white rice
with pork drippings or quarter-pound cheeseburgers with
french fries and soda) may be more relevant.
Assessing an individual for diabetes risk seems relatively
straightforward until one realizes that Southeast Asians tend
to develop the disease at a younger age and lower BMI.
Disease management in Southeast Asian patients is also
complicated by a greater prominence of postprandial hyper-
glycemia and renal complications.
Economics and education affect the likelihood that a
health care intervention, regardless of its benefit, will be
adopted and faithfully used by a particular segment of
society. Task force members noted that the acceptance of
dietitians or nutrition counselors, for instance, is low in
Southeast Asia because the importance of such individuals
is probably undervalued or misunderstood, not only by
patients but occasionally by physicians, too. The cost and
relative inaccessibility of these allied professionals may
impede their participation in health care, especially when
community resources are not available for targeted educa-
tion. Moreover, broader education in the form of CPGs for
comprehensive care of patients with diabetes as well as
specific lifestyle interventions are needed worldwide, but
guidance comes mostly from developed countries, especial-
ly Europe and North America, where interpretation of so-
phisticated recommendations is easier than in developing
non-English-speaking nations. Couple this problem to a lack
of familiarity with nutrition therapy in general and prepared
liquid formulas in particular, and the likelihood of effective
nutrition management is greatly reduced.
In response to these problems, we developed the tDNA.
It has four major strengths: 1) simplicity that fosters not only
an understanding of diabetes-specific nutrition therapy but
also the cultural adaptation necessary for worldwide imple-
mentation; 2) incorporation of advice from national and
international associations and respected publications; 3) in-
clusion of important clinical evidence and experience from
multinational health care stakeholders who contributed to
Curr Diab Rep (2012) 12:180–194 189the developmental process; 4) openness to scientific and
cultural adaptation.
Dietary and culinary habits within many diverse global
communities must still be identified, and guidance must be
further tailored along ethnic and cultural lines. To reach this
end point within the tDNA program, diabetes and nutrition
experts from around the world continue to be organized, fa-
miliarized with program goals, and invited to contribute to the
transculturalization process. Adapted versions of the algorithm
have already emerged for Southeast Asian and Asian Indian
populations [57, 58]. Implementation will require education
initiatives and follow-up assessments to determine if clinical
benefit is truly achieved. These activities are currently being
planned within thetDNA program. Iffound to besuccessful in
optimizingcomprehensivediabetescare,the tDNAandrelated
educational resources will be made available for widespread
dissemination and worldwide implementation.
Conclusions
The algorithm presented here incorporates established
standards used for CPG development, adaptation, and im-
plementation. It is comprehensive and authoritative, yet
brief and easy to use. Importantly, it is designed for sim-
plicity and global cultural adaptation, or transculturalization.
In large part, it conveys established clinical guidance from
highly respected organizations for nutrition therapy and
lifestyle management. It also references calorie augmenta-
tion or replacement with diabetes-specific liquid meals, a
relatively novel addition to traditional nutrition therapy. It
remains open to modification of content and context.
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